留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

晚期胰腺导管腺癌药物治疗进展

程月鹃 管梅 王湘 白春梅

程月鹃, 管梅, 王湘, 白春梅. 晚期胰腺导管腺癌药物治疗进展[J]. 协和医学杂志, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139
引用本文: 程月鹃, 管梅, 王湘, 白春梅. 晚期胰腺导管腺癌药物治疗进展[J]. 协和医学杂志, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139
CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei. Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139
Citation: CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei. Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 341-348. doi: 10.12290/xhyxzz.2021-0139

晚期胰腺导管腺癌药物治疗进展

doi: 10.12290/xhyxzz.2021-0139
详细信息
    通讯作者:

    白春梅,E-mail: baichunmei1964@163.com

  • 中图分类号: R735.9

Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma

More Information
  • 摘要: 由于特殊的免疫抑制微环境以及缺少可作为药物靶点的驱动基因突变, 胰腺导管腺癌(pancreatic ductal adenocarcinoma, PDAC)患者的预后较其他恶性肿瘤患者差。目前化疗仍是多数晚期PDAC的主要治疗手段。近年来, 随着抗肿瘤药物不断更新及二代测序技术进一步普及, 基因检测可指导部分晚期PDAC患者化疗与分子靶向药物治疗方案的制订。国内外指南均推荐所有晚期PDAC患者接受体系及胚系基因检测, 以确定最佳治疗策略。当前, 针对PDAC主要驱动基因KRAS的分子靶向药物、肿瘤疫苗及抗肿瘤代谢药物等仍处于临床研究阶段。本文将对PDAC药物治疗现状及进展作一综述。
    作者贡献:程月鹃负责资料收集及论文撰写;管梅、王湘、白春梅负责论文审校。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] American Cancer Society. Facts & Figures 2014[EB/OL]. [2021-02-20]. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html.
    [2] American Cancer Society. Facts & Figures 2020[EB/OL]. [2021-12-20]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf.
    [3] Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020, 21: e342-e349. doi:  10.1016/S1470-2045(20)30073-5
    [4] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6: e555-e567. doi:  10.1016/S2214-109X(18)30127-X
    [5] SEER Cancer Stat Facts: Pancreatic Cancer[EB/OL]. (2021-04-15)[2021-12-20]. https://seer.cancer.gov/statfacts/html/pancreas.html.
    [6] O'Reilly EM, Surinach A, Wu Z, et al. Real-world patterns of care among patients with metastatic pancreatic cancer (mPC)[J]. J Clin Oncol, 2020, 38: 666.
    [7] Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15: 2403-2413. doi:  10.1200/JCO.1997.15.6.2403
    [8] Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31: 1640-1648. doi:  10.1200/JCO.2012.43.3680
    [9] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364: 1817-1825. doi:  10.1056/NEJMoa1011923
    [10] Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369: 1691-1703. doi:  10.1056/NEJMoa1304369
    [11] Kang J, Hwang I, Yoo C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis[J]. Invest New Drugs, 2018, 36: 732-741. doi:  10.1007/s10637-018-0598-5
    [12] Nakazawa J, Otsuka T, Shimokawa M, et al. A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study[J]. Ann Oncol, 2019, 30: iv17-iv18.
    [13] Pusceddu S, Ghidini M, Torchio M, et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis[J]. Cancers (Basel), 2019, 11: 484. doi:  10.3390/cancers11040484
    [14] Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation[J]. Br J Cancer, 2020, 122: 333-339. doi:  10.1038/s41416-019-0582-7
    [15] Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers[J]. Br J Cancer, 2014, 111: 1132-1138. doi:  10.1038/bjc.2014.418
    [16] O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase Ⅱ Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation[J]. J Clin Oncol, 2020, 38: 1378-1388. doi:  10.1200/JCO.19.02931
    [17] Pishvaian MJ, Blais EM, Brody JR, et al. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program[J]. JCO Precis Oncol, 2019, 3: 1-10.
    [18] Park W, Chen J, Chou JF, et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection[J]. Clin Cancer Res, 2020, 26: 3239-3247. doi:  10.1158/1078-0432.CCR-20-0418
    [19] National Comprehensive Cancer Network®(NCCN®). Pancreatic Adenocarcinoma. Version 2.2021[EB/OL]. (2021-02-25)[2021-12-20]. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
    [20] 中国临床肿瘤学会. 胰腺癌诊疗指南2020[EB/OL ]. (2020-11-09)[2021-12-20]. http://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/202011/2020119641817.pdf.

    Chinese Society of Clinical Oncology(CSCO). Guidelines of pancreatic cancer 2020[EB/OL ]. (2020-11-09)[2021-12-20]. http://meeting.csco.org.cn/pdf/web/viewer.html?file=/upload/Periodical/202011/2020119641817.pdf.
    [21] Casolino R, Paiella S, Azzolina D, et al. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis[J]. J Clin Oncol, 2021, 39: 2617-2631. doi:  10.1200/JCO.20.03238
    [22] Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 387: 545-557. doi:  10.1016/S0140-6736(15)00986-1
    [23] Oettle H, Riess H, Stieler JM, et al. Second-line oxalipla-tin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial[J]. J Clin Oncol, 2014, 32: 2423-2429. doi:  10.1200/JCO.2013.53.6995
    [24] Gill S, Ko YJ, Cripps C, et al. PANCREOX: A Randomized Phase Ⅲ Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy[J]. J Clin Oncol, 2016, 34: 3914-3920. doi:  10.1200/JCO.2016.68.5776
    [25] Sawada M, Kasuga A, Mie T, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer[J]. BMC Cancer, 2020, 20: 449. doi:  10.1186/s12885-020-06945-8
    [26] Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort[J]. Br J Cancer, 2015, 113: 989-995. doi:  10.1038/bjc.2015.328
    [27] Mita N, Iwashita T, Uemura S, et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure[J]. J Clin Med, 2019, 8: 761. doi:  10.3390/jcm8060761
    [28] Baron MK, Wang X, Nevala-Plagemann C, et al. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma[J]. Pancreas, 2021, 50: 796-802. doi:  10.1097/MPA.0000000000001844
    [29] Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25: 1960-1966. doi:  10.1200/JCO.2006.07.9525
    [30] Dreyer SB, Chang DK, Bailey P, et al. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development[J]. Clin Cancer Res, 2017, 23: 1638-1646. doi:  10.1158/1078-0432.CCR-16-2411
    [31] Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovar-ian Cancer[J]. N Engl J Med, 2018, 379: 2495-2505. doi:  10.1056/NEJMoa1810858
    [32] Reiss KA, Mick R, O'Hara MH, et al. Phase Ⅱ Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2[J]. J Clin Oncol, 2021, 39: 2497-2505. doi:  10.1200/JCO.21.00003
    [33] Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28: 2429-2435. doi:  10.1093/annonc/mdx343
    [34] Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors[J]. N Engl J Med, 2020, 383: 1207-1217. doi:  10.1056/NEJMoa1917239
    [35] Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients[J]. Cancer Discov, 2020, 10: 54-71. doi:  10.1158/2159-8290.CD-19-1167
    [36] Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor[J]. J Med Chem, 2021. doi:  10.1021/acs.jmedchem.1c01688.
    [37] AACR-NCI-EORTC virtual international conference on molecular targets and cancer therapeutics. Discovery and Development of RAS(ON) Inhibitors Beyond KRASG12C[EB/OL ]. (2021-10-09)[2021-12-20]. https://ir.revmed.com/static-files/ad588f56-5608-4ad6-9816-be40b38eb974.
    [38] Kato S, Adashek JJ, Shaya J, et al. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics[J]. Clin Cancer Res, 2021, 27: 2792-2797. doi:  10.1158/1078-0432.CCR-20-3761
    [39] Jones MR, Williamson LM, Topham JT, et al. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma[J]. Clin Cancer Res, 2019, 25: 4674-4681.
    [40] Heining C, Horak P, Uhrig S, et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer[J]. Cancer Discov, 2018, 8: 1087-1095. doi:  10.1158/2159-8290.CD-18-0036
    [41] Pishvaian MJ, Rolfo CD, Liu SV, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions[J]. J Clin Oncol, 2018, 36: 521.
    [42] O'Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion[J]. Ann Oncol, 2019, 30: viii36-viii40. doi:  10.1093/annonc/mdz385
    [43] Singhi AD, Ali SM, Lacy J, et al. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma[J]. J Natl Compr Canc Netw, 2017, 15: 555-562. doi:  10.6004/jnccn.2017.0058
    [44] Gower A, Golestany B, Gong J, et al. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib[J]. JCO Precis Oncol, 2020, 4: PO. 19.00365.
    [45] Guan M, Bender RJ, Pishvaian MJ, et al. Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs)[J]. J Clin Oncol, 2018, 36: 214.
    [46] Li H-S, Yang K, Wang Y. Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report[J]. Gastroenterol Rep, 2021: goab031. doi:  10.1093/gastro/goab031.
    [47] Schram AM, O'Reilly EM, O'Kane GM, et al. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions[J]. J Clin Oncol, 2021, 39: 3003. doi:  10.1200/JCO.2021.39.15_suppl.3003
    [48] Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500: 415-421. doi:  10.1038/nature12477
    [49] O'Reilly EM, Oh DY, Dhani N, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancre-atic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5: 1431-1438. doi:  10.1001/jamaoncol.2019.1588
    [50] Renouf DJ, Knox JJ, Kavan P, et al. LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase Ⅱ study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)[J]. Ann Oncol, 2020, 31: S1195. doi:  10.1016/j.annonc.2020.08.2300
    [51] Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial[J]. Nat Med, 2020, 26: 878-885. doi:  10.1038/s41591-020-0880-x
    [52] O'Hara MH, O'Reilly EM, Wolff RA, et al. Gemcitabine (Gem) and nab-paclitaxel (NP) ±nivolumab (nivo) ±CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results[J]. J Clin Oncol, 2021, 39: 4019. doi:  10.1200/JCO.2021.39.15_suppl.4019
    [53] Le DT, Picozzi VJ, Ko AH, et al. Results from a Phase Ⅱb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)[J]. Clin Cancer Res, 2019, 25: 5493-5502. doi:  10.1158/1078-0432.CCR-18-2992
    [54] Tsujikawa T, Crocenzi T, Durham JN, et al. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer[J]. Clin Cancer Res, 2020, 26: 3578-3588. doi:  10.1158/1078-0432.CCR-19-3978
    [55] Wu AA, Bever KM, Ho WJ, et al. A Phase Ⅱ Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer[J]. Clin Cancer Res, 2020, 26: 5129-5139. doi:  10.1158/1078-0432.CCR-20-1025
    [56] Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients[J]. Oncotarget, 2015, 6: 24560-24570. doi:  10.18632/oncotarget.4183
    [57] Alistar A, Morris BB, Desnoyer R, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial[J]. Lancet Oncol, 2017, 18: 770-778. doi:  10.1016/S1470-2045(17)30314-5
    [58] Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial[J]. Lancet Oncol, 2020, 21: 508-518. doi:  10.1016/S1470-2045(20)30074-7
  • 加载中
计量
  • 文章访问数:  423
  • HTML全文浏览量:  63
  • PDF下载量:  55
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-01
  • 录用日期:  2021-02-26
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!